The Usefulness of Charlson Comorbidity Index (CCI) Scoring in Predicting All-cause Mortality in Outpatients with Clinical Diagnoses of COPD

Overview

Journal J Multimorb Comorb

Date 2025 Jan 29

PMID 39877897

Authors

Kevin Ly

Dorothy Wakefield

Richard ZuWallack

Affiliations

Soon will be listed here.

Abstract

Background: Since comorbid conditions are frequently present in chronic obstructive pulmonary disease (COPD) and affect outcome, a composite scoring system to quantify comorbidity might be helpful in assessing mortality risk.

Methods: We tested the hypothesis that the Charlson Comorbidity Index (CCI) score at the time of an outpatient medical clinic encounter for COPD predicts all-cause mortality. Cox Proportional Hazards analyses were used in 200 randomly selected patients to relate CCI scores to all-cause mortality out to 5 years.

Results: Mean age was 62 ± 10 years, 56% were female, FEV1 was 62%, CCI was 3.08 ± 2.30, and 30% had a CCI ≥ 4, indicating 3 or more comorbid conditions. All-cause mortality was 8.5% and 20% at 3 and 5 years, respectively. In univariate testing, the CCI score and hospitalizations predicted mortality, but FEV1 did not. In multivariable testing, which included covariates of age, sex, socioeconomic status, race, FEV1 percent-predicted, and all-cause hospitalizations in the preceding year, CCI expressed as a continuous variable strongly predicted mortality: hazard ratio (HR) 1.38 for each unit increase in the score (p < 0.0001). While 1 or 2 comorbid conditions were not significantly related to mortality, 3 or more comorbid conditions (compared to none) strongly predicted mortality: HR 9.80, 95% CI 3.80 to 25.00.

Conclusion: Comorbidity, assessed with the CCI, is strongly predictive of mortality in outpatients with a clinical diagnosis of COPD, and this relationship appears to be non-linear. This instrument may be useful in determining prognosis in this population.

References

Celli B, Cote C, Lareau S, Meek P . Predictors of Survival in COPD: more than just the FEV1. Respir Med. 2008; 102 Suppl 1:S27-35. DOI: 10.1016/S0954-6111(08)70005-2. View

Kieszak S, Flanders W, Kosinski A, Shipp C, KARP H . A comparison of the Charlson comorbidity index derived from medical record data and administrative billing data. J Clin Epidemiol. 1999; 52(2):137-42. DOI: 10.1016/s0895-4356(98)00154-1. View

Deyo R, Cherkin D, Ciol M . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613-9. DOI: 10.1016/0895-4356(92)90133-8. View

Charlson M, Charlson R, Peterson J, Marinopoulos S, Briggs W, Hollenberg J . The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008; 61(12):1234-1240. DOI: 10.1016/j.jclinepi.2008.01.006. View

Anthonisen N, Wright E, Hodgkin J . Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1986; 133(1):14-20. DOI: 10.1164/arrd.1986.133.1.14. View

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43(11):1130-9. DOI: 10.1097/01.mlr.0000182534.19832.83. View

Feinstein A . THE PRE-THERAPEUTIC CLASSIFICATION OF CO-MORBIDITY IN CHRONIC DISEASE. J Chronic Dis. 2015; 23(7):455-68. DOI: 10.1016/0021-9681(70)90054-8. View

Valderas J, Starfield B, Sibbald B, Salisbury C, Roland M . Defining comorbidity: implications for understanding health and health services. Ann Fam Med. 2009; 7(4):357-63. PMC: 2713155. DOI: 10.1370/afm.983. View

Owusuaa C, Dijkland S, Nieboer D, van der Rijt C, van der Heide A . Predictors of mortality in chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med. 2022; 22(1):125. PMC: 8978392. DOI: 10.1186/s12890-022-01911-5. View

10.

Almagro P, Martinez-Camblor P, Soriano J, Marin J, Alfageme I, Casanova C . Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. PLoS One. 2014; 9(2):e89866. PMC: 3937394. DOI: 10.1371/journal.pone.0089866. View

11.

Charlson M, Carrozzino D, Guidi J, Patierno C . Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. Psychother Psychosom. 2022; 91(1):8-35. DOI: 10.1159/000521288. View

12.

Prommik P, Tootsi K, Saluse T, Strauss E, Kolk H, Martson A . Simple Excel and ICD-10 based dataset calculator for the Charlson and Elixhauser comorbidity indices. BMC Med Res Methodol. 2022; 22(1):4. PMC: 8742382. DOI: 10.1186/s12874-021-01492-7. View

13.

Lane N, Maxwell C, Gruneir A, Bronskill S, Wodchis W . Absence of a Socioeconomic Gradient in Older Adults' Survival with Multiple Chronic Conditions. EBioMedicine. 2016; 2(12):2094-100. PMC: 4703730. DOI: 10.1016/j.ebiom.2015.11.018. View

14.

Ellingsen J, Johansson G, Larsson K, Lisspers K, Malinovschi A, Stallberg B . Impact of Comorbidities and Commonly Used Drugs on Mortality in COPD - Real-World Data from a Primary Care Setting. Int J Chron Obstruct Pulmon Dis. 2020; 15:235-245. PMC: 7006848. DOI: 10.2147/COPD.S231296. View

15.

McGarvey L, Magder S, Burkhart D, Kesten S, Liu D, Manuel R . Cause-specific mortality adjudication in the UPLIFT® COPD trial: findings and recommendations. Respir Med. 2011; 106(4):515-21. DOI: 10.1016/j.rmed.2011.10.009. View

16.

Murphy S, Kochanek K, Xu J, Arias E . Mortality in the United States, 2020. NCHS Data Brief. 2022; (427):1-8. View

17.

Halpin D . Mortality of patients with COPD. Expert Rev Respir Med. 2024; 18(6):381-395. DOI: 10.1080/17476348.2024.2375416. View

18.

Pinto-Plata V, Cote C, Cabral H, Taylor J, Celli B . The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004; 23(1):28-33. DOI: 10.1183/09031936.03.00034603. View

19.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

20.

Sin D, Anthonisen N, Soriano J, Agusti A . Mortality in COPD: Role of comorbidities. Eur Respir J. 2006; 28(6):1245-57. DOI: 10.1183/09031936.00133805. View